FDA Adverse Event Injury Summary report: N

INTRALASE FS2

MDR report key: 8659678 · Received May 31, 2019

Report

Report Number
3006695864-2019-00444
Event Type
Injury
Date Received
May 31, 2019
Date of Event
May 6, 2019
Report Date
November 12, 2020
Manufacturer
JOHNSON & JOHNSON SURGICAL VISION, INC.
Product Code
HNO
UDI-DI
05050474573451
PMA / PMN Number
K060372
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IA, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 0

THIS CORRECTION MDR IS BEING SUBMITTED TO ADDRESS INACCURATE INFORMATION IN SECTION F ON THE XML VERSION OF THE PREVIOUS SUBMISSION CAUSED BY A SOFTWARE GLITCH IN THE TRANSMISSION PROCESS. THE INTERNAL NON-CONFORMANCE NUMBERS FOR THIS SOFTWARE ISSUE ARE NR-(B)(4) AND CAPA-010215.

Additional Manufacturer Narrative · 1

A REVIEW OF RECORDS RELATED TO THE DEVICE INCLUDING LABELING, COMPLAINT TRENDING, AND RISK DOCUMENTATION WILL BE PERFORMED. UPON COMPLETION OF THIS REVIEW, IF THERE IS ANY FURTHER RELEVANT INFORMATION OBTAINED, A SUPPLEMENTAL MEDWATCH WILL BE FILED. ALL PERTINENT INFORMATION AVAILABLE TO JOHNSON & JOHNSON SURGICAL VISION, INC. HAS BEEN SUBMITTED.

Description of Event or Problem · 1

IT WAS REPORTED THAT A LASER VISION CORRECTION PATIENT HAD SURGERY ON (B)(6) 2019 AND PRESENTED ON (B)(6) 2019 WITH STAGE 2 DIFFUSE LAMELLAR KERATITIS (DLK) ON BOTH EYES (OU) THAT WAS DISCOVERED AT A POST TREATMENT. TOPICAL STEROID DOSAGE WAS INCREASED AND AN ORAL STEROID (MEDROL PACK) WAS PRESCRIBED. PATIENT'S CHIEF COMPLAINT WAS OF DRY EYE AND CLOUDY VISUAL ACUITY. IT WAS STATED THAT THE PATIENT HAD NO LOSS OF BEST CORRECTED VISUAL ACUITY (BCVA). THE PATIENT REPORTED THE SYMPTOMS ARE NOT INTERFERING WITH DAILY ACTIVITIES. BCVA FROM (B)(6) 2019: RIGHT EYE PRE-OP 20/15 -2.25 X -.25 X 133. LEFT EYE PRE-OP 20/15 -1.75 X -.25 X 9.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
454166 INTRALASE FS2 FEMTOSECOND LASER HNO JOHNSON & JOHNSON SURGICAL VISION, INC. 20005D 05050474573451

Patients

Seq Age Sex Outcome Treatment
1 32 YR Required Intervention WAVELIGHT: (B)(4)| WAVELIGHT: (B)(4)